Literature DB >> 29040038

Ferumoxytol-enhanced MR Angiography for Vascular Access Mapping before Transcatheter Aortic Valve Replacement in Patients with Renal Impairment: A Step Toward Patient-specific Care.

Kim-Lien Nguyen1, John M Moriarty1, Adam N Plotnik1, Olcay Aksoy1, Takegawa Yoshida1, Richard J Shemin1, William M Suh1, J Paul Finn1.   

Abstract

Purpose To assess the technical feasibility of the use of ferumoxytol-enhanced (FE) magnetic resonance (MR) angiography for vascular mapping before transcatheter aortic valve replacement in patients with renal impairment. Materials and Methods This was an institutional review board-approved and HIPAA-compliant study. FE MR angiography was performed at 3.0 T or 1.5 T. Unenhanced computed tomographic (CT) images were used to overlay vascular calcification on FE MR angiographic images as composite fused three-dimensional data. Image quality of the subclavian and aortoiliofemoral arterial tree and confidence in the assessment of calcification were evaluated by using a four-point scale (4 = excellent vascular definition or strong confidence). Signal intensity nonuniformity as reflected by the heterogeneity index (ratio between the mean standard deviation of luminal signal intensity and the mean luminal signal intensity), signal-to-noise ratio, and consistency of luminal diameter measurements were quantified. Findings at FE MR angiography were compared with pelvic angiograms. Results Twenty-six patients underwent FE MR angiography without adverse events. A total of 286 named vascular segments were scored. The image quality score was 4 for 99% (283 of 286) of the segments (κ = 0.9). There was moderate to strong confidence in the ability to assess vascular calcific morphology in all studies with complementary unenhanced CT. The steady-state luminal heterogeneity index was low, and signal-to-noise ratio was high. Interobserver luminal measurements were reliable (intraclass correlation coefficient, 0.98; 95% confidence interval: 0.98, 0.99). FE MR angiographic findings were consistent with correlative pelvic angiograms in all 16 patients for whom the latter were available. Conclusion In patients with renal impairment undergoing transcatheter aortic valve replacement, FE MR angiography is technically feasible and offers reliable vascular mapping without exposure to iodine- or gadolinium-based contrast agents. Thus, the total cumulative dose of iodine-based contrast material is minimized and the risk of acute nephropathy is reduced. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29040038     DOI: 10.1148/radiol.2017162899

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

1.  Minimizing table time in patients with claustrophobia using focused ferumoxytol-enhanced MR angiography (f-FEMRA): a feasibility study.

Authors:  Puja Shahrouki; Kim-Lien Nguyen; John M Moriarty; Adam N Plotnik; Takegawa Yoshida; J Paul Finn
Journal:  Br J Radiol       Date:  2021-09-01       Impact factor: 3.629

2.  Contrast-enhanced MR Angiography without Gadolinium-based Contrast Material: Clinical Applications Using Ferumoxytol.

Authors:  Mohammad H Jalili; Tiffany Yu; Cameron Hassani; Ashley E Prosper; J Paul Finn; Arash Bedayat
Journal:  Radiol Cardiothorac Imaging       Date:  2022-08-04

Review 3.  State-of-the-Art Imaging for the Evaluation of Pulmonary Embolism.

Authors:  Leonid Roshkovan; Harold Litt
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-08-07

Review 4.  Modern iron replacement therapy: clinical and pathophysiological insights.

Authors:  Domenico Girelli; Sara Ugolini; Fabiana Busti; Giacomo Marchi; Annalisa Castagna
Journal:  Int J Hematol       Date:  2017-12-01       Impact factor: 2.490

5.  Intermodality feature fusion combining unenhanced computed tomography and ferumoxytol-enhanced magnetic resonance angiography for patient-specific vascular mapping in renal impairment.

Authors:  Takegawa Yoshida; Kim-Lien Nguyen; Puja Shahrouki; William J Quinones-Baldrich; Peter F Lawrence; J Paul Finn
Journal:  J Vasc Surg       Date:  2019-11-14       Impact factor: 4.860

6.  Ferumoxytol-enhanced ultrashort TE MRA and quantitative morphometry of the human kidney vasculature.

Authors:  Liam Timms; Tianyi Zhou; Yue Lyu; Ju Qiao; Vishala Mishra; Rita Maria Lahoud; Gayatri Veeramani Jayaraman; Andrew S Allegretti; David Drew; Ravi T Seethamraju; Mukesh Harisinghani; Srinivas Sridhar
Journal:  Abdom Radiol (NY)       Date:  2021-03-05

Review 7.  SCMR Position Paper (2020) on clinical indications for cardiovascular magnetic resonance.

Authors:  Tim Leiner; Jan Bogaert; Matthias G Friedrich; Raad Mohiaddin; Vivek Muthurangu; Saul Myerson; Andrew J Powell; Subha V Raman; Dudley J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2020-11-09       Impact factor: 5.364

Review 8.  Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.

Authors:  Yue Huang; Jessica C Hsu; Hyun Koo; David P Cormode
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

9.  Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI.

Authors:  Kim-Lien Nguyen; Takegawa Yoshida; Nikhita Kathuria-Prakash; Islam H Zaki; Csanad G Varallyay; Scott I Semple; Rola Saouaf; Cynthia K Rigsby; Sokratis Stoumpos; Kevin K Whitehead; Lindsay M Griffin; David Saloner; Michael D Hope; Martin R Prince; Mark A Fogel; Mark L Schiebler; Giles H Roditi; Aleksandra Radjenovic; David E Newby; Edward A Neuwelt; Mustafa R Bashir; Peng Hu; J Paul Finn
Journal:  Radiology       Date:  2019-10-22       Impact factor: 11.105

10.  One-pot synthesis of carboxymethyl-dextran coated iron oxide nanoparticles (CION) for preclinical fMRI and MRA applications.

Authors:  Manasmita Das; Esteban A Oyarzabal; Lars Chen; Sung-Ho Lee; Neal Shah; Gabby Gerlach; Weiting Zhang; Tzu-Hao Harry Chao; Nathalie Van Den Berge; Carolyn Liu; Carrie Donley; Stephanie A Montgomery; Yen-Yu Ian Shih
Journal:  Neuroimage       Date:  2021-06-09       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.